Cromodata becomes first Argentina startup to graduate from PharmStars

PharmStars said Buenos Aires-based Cromodata is the first Argentinian startup to complete its accelerator, finishing a 10-week program at the end of 2025. The milestone gives Cromodata a stronger path into the U.S. pharma market and highlights growing demand for Latin American clinical data tools.

Why it matters: - Cromodata’s graduation gives the Buenos Aires startup a new credibility boost with global pharmaceutical companies. - The result also marks a regional milestone: Cromodata is the first startup from Argentina to graduate from PharmStars. - PharmStars said the program helps digital health startups bridge the gap with pharma buyers and speed adoption of new tools.

What happened: - PharmStars announced that Cromodata completed PharmaU, the accelerator’s 10-week educational and mentoring program, at the end of 2025. - Cromodata was one of 11 startups in a cohort focused on innovations in data management and insights. - The startup presented at the PharmStars Startup Showcase in Boston and met one-on-one with pharma members. - Cromodata also became the first Argentinian startup to receive an investment from the PharmStars Ventures fund.

The details: - PharmStars said the 9th cohort drew startups from 19 countries in a competitive application process. - Cromodata operates a compliant real-world clinical data platform. - The platform integrates, de-identifies and standardizes patient data from hospitals and healthcare systems across Latin America. - Cromodata uses an AI-driven quality assurance process to turn scattered clinical information into multimodal datasets. - Pharmaceutical companies use the data to support clinical research, evaluate market opportunities and make decisions across the region. - The startup said it already worked with two pharmaceutical companies to optimize site selection, accelerate cohort validation and reduce risk in Latin American market entry. - Cromodata said it joined PharmStars to improve how it communicated its value and to build a stronger path into the U.S. pharma market. - Keila Fara Barral Masri, Cromodata co-founder and CEO, said the program helped the company adapt its business plan and language for broader stakeholders and led to new business opportunities. - Juan Pablo Merea Otermin, Cromodata co-founder and COO, said direct interaction with pharma leaders and the program’s Fireside chats helped clarify the problems pharma companies are trying to solve. - PharmStars CEO Naomi Fried said Cromodata’s approach to turning fragmented Latin American clinical data into usable pharma insights is “powerful and unique.”

Between the lines: - Cromodata’s win underscores how regional health-data startups can use accelerator access to break into the U.S. pharma ecosystem. - The company’s focus on compliant, standardized Latin American data fits a broader need for better real-world evidence and faster market intelligence. - PharmStars is using its startup-member model to position itself as a connector between pharma buyers and digital health vendors.

What's next: - PharmStars will begin accepting applications for its next cohort in early 2027. - Digital health startups can sign up for the PharmStars newsletter at more information to get updates. - PharmStars is also seeking a limited number of additional pharma and biotech members. - Membership details are available at membership information. - Cromodata said it will keep expanding globally and building relationships with pharmaceutical companies. - More information about Cromodata is available at the company’s website.